CL2013000901A1 - Anticuerpo que se fija sobre la tweak humana; variante quimerica, humanizada o reducida del epitope de las celulas t; composicion farmaceutica que comprende el anticuerpo; uso del anticuerpo para tratar cancer, enfermedades autoinmunes y otras enfermedades; acido nucleico, vectores de expresion y celula huesped que comprenden la secuencia codificante del anticuerpo antes mencionado. - Google Patents

Anticuerpo que se fija sobre la tweak humana; variante quimerica, humanizada o reducida del epitope de las celulas t; composicion farmaceutica que comprende el anticuerpo; uso del anticuerpo para tratar cancer, enfermedades autoinmunes y otras enfermedades; acido nucleico, vectores de expresion y celula huesped que comprenden la secuencia codificante del anticuerpo antes mencionado.

Info

Publication number
CL2013000901A1
CL2013000901A1 CL2013000901A CL2013000901A CL2013000901A1 CL 2013000901 A1 CL2013000901 A1 CL 2013000901A1 CL 2013000901 A CL2013000901 A CL 2013000901A CL 2013000901 A CL2013000901 A CL 2013000901A CL 2013000901 A1 CL2013000901 A1 CL 2013000901A1
Authority
CL
Chile
Prior art keywords
antibody
diseases
humanized
chimeric
nucleic acid
Prior art date
Application number
CL2013000901A
Other languages
English (en)
Inventor
Monika Baehner
Hendrik Knoetgen
Jens Niewoehner
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2013000901A1 publication Critical patent/CL2013000901A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
CL2013000901A 2010-10-05 2013-04-04 Anticuerpo que se fija sobre la tweak humana; variante quimerica, humanizada o reducida del epitope de las celulas t; composicion farmaceutica que comprende el anticuerpo; uso del anticuerpo para tratar cancer, enfermedades autoinmunes y otras enfermedades; acido nucleico, vectores de expresion y celula huesped que comprenden la secuencia codificante del anticuerpo antes mencionado. CL2013000901A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10186536 2010-10-05

Publications (1)

Publication Number Publication Date
CL2013000901A1 true CL2013000901A1 (es) 2013-11-29

Family

ID=43086385

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013000901A CL2013000901A1 (es) 2010-10-05 2013-04-04 Anticuerpo que se fija sobre la tweak humana; variante quimerica, humanizada o reducida del epitope de las celulas t; composicion farmaceutica que comprende el anticuerpo; uso del anticuerpo para tratar cancer, enfermedades autoinmunes y otras enfermedades; acido nucleico, vectores de expresion y celula huesped que comprenden la secuencia codificante del anticuerpo antes mencionado.

Country Status (21)

Country Link
US (1) US9187564B2 (es)
EP (1) EP2625200A1 (es)
JP (1) JP5941049B2 (es)
KR (1) KR101584416B1 (es)
CN (1) CN103154029B (es)
AR (1) AR083336A1 (es)
AU (1) AU2011311673B2 (es)
BR (1) BR112013007293A2 (es)
CA (1) CA2809632A1 (es)
CL (1) CL2013000901A1 (es)
CR (1) CR20130108A (es)
EA (1) EA201300418A1 (es)
EC (1) ECSP13012542A (es)
MA (1) MA34642B1 (es)
MX (1) MX343114B (es)
NZ (1) NZ607588A (es)
PE (1) PE20131411A1 (es)
PH (1) PH12013500506A1 (es)
SG (1) SG188605A1 (es)
TW (1) TWI482630B (es)
WO (1) WO2012045671A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE200100372A (et) * 1999-01-15 2002-10-15 Biogen, Incorporated TWEAK-valgu ja TWEAK-valgu retseptori antagonistid ja nende kasutamine immuunhaiguste raviks
CN103536916B (zh) 2002-04-09 2016-08-17 比奥根Ma公司 用于治疗tweak相关病症的方法
US20090124993A1 (en) 2005-02-17 2009-05-14 Burkly Linda C Treating neurological disorders
WO2006122187A2 (en) 2005-05-10 2006-11-16 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
EP2681239B8 (en) 2011-02-28 2015-09-09 F. Hoffmann-La Roche AG Antigen binding proteins
AR085403A1 (es) 2011-02-28 2013-09-25 Hoffmann La Roche Proteinas monovalentes que se unen a antigenos
CA2868404A1 (en) 2012-04-05 2013-10-10 F. Hoffmann-La Roche Ag Bispecific antibodies against human tweak and human il17 and uses thereof
JP2016000003A (ja) * 2013-04-19 2016-01-07 アステラス製薬株式会社 新規抗ヒトｔｗｅａｋ抗体
WO2015051234A2 (en) * 2013-10-04 2015-04-09 Biogen Idec Ma Inc. Tweak antagonists for treating lupus nephritis and muscle atrophy
CN106573986A (zh) * 2014-07-29 2017-04-19 豪夫迈·罗氏有限公司 多特异性抗体
MY204672A (en) 2018-10-31 2024-09-09 Astellas Pharma Inc Anti-human fn14 antibody
CN112180100A (zh) * 2020-09-27 2021-01-05 西安交通大学 Tweak作为鉴别不同类型银屑病的分子标志物的应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
JP3537535B2 (ja) 1994-07-14 2004-06-14 株式会社中埜酢店 免疫グロブリンｇ結合糖鎖構造に基づく臨床検査方法
WO1997016064A1 (en) 1995-11-03 1997-05-09 The Mount Sinai Medical Center Methods and compositions for the reduction of xenotransplantation rejection
EP0956351B1 (en) 1996-08-07 2005-10-19 Biogen Idec MA Inc. A tumor necrosis factor related ligand
WO1998033523A1 (en) 1997-01-31 1998-08-06 Biovation Limited Vaccination methods and molecules
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
BRPI9910332B8 (pt) 1998-05-06 2021-05-25 Genentech Inc método para purificação de um polipeptídio a partir de uma composição
EP1051432B1 (en) 1998-12-08 2007-01-24 Biovation Limited Method for reducing immunogenicity of proteins
EE200100372A (et) 1999-01-15 2002-10-15 Biogen, Incorporated TWEAK-valgu ja TWEAK-valgu retseptori antagonistid ja nende kasutamine immuunhaiguste raviks
CN103536916B (zh) 2002-04-09 2016-08-17 比奥根Ma公司 用于治疗tweak相关病症的方法
AU2004242846A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
US7109304B2 (en) 2003-07-31 2006-09-19 Immunomedics, Inc. Humanized anti-CD19 antibodies
AR045614A1 (es) 2003-09-10 2005-11-02 Hoffmann La Roche Anticuerpos contra el recepctor de la interleuquina- 1 y los usos de los mismos
WO2006052926A2 (en) 2004-11-08 2006-05-18 University Of Maryland, Baltimore Tweak as a therapeutic target for treating central nervous system diseases associated with cerebral edema and and cell death
HUE025945T2 (en) 2005-02-15 2016-07-28 Univ Duke Anti-CD19 antibodies and their applications in oncology
WO2006088890A2 (en) 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating stroke
US20090124993A1 (en) 2005-02-17 2009-05-14 Burkly Linda C Treating neurological disorders
AU2006220825A1 (en) 2005-03-07 2006-09-14 Genentech, Inc. Methods and compositions for modulating TWEAK and FN14 activity
TW200720289A (en) 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof
WO2006122187A2 (en) 2005-05-10 2006-11-16 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
NZ564092A (en) 2005-05-27 2010-05-28 Biogen Idec Inc TWEAK binding antibodies
WO2006130429A2 (en) 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Treatment of cancer
WO2006133450A2 (en) 2005-06-08 2006-12-14 Duke University Anti-cd19 antibody therapy for the transplantation
EP1899379B1 (en) 2005-06-20 2018-04-11 E. R. Squibb & Sons, L.L.C. Cd19 antibodies and their uses
EP1937306B1 (en) 2005-08-19 2016-02-17 Janssen Biotech, Inc. Proteolysis resistant antibody preparations
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
WO2008057634A2 (en) 2006-10-26 2008-05-15 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
DE102005060813A1 (de) 2005-12-20 2007-06-28 Rheinisch-Westfälische Technische Hochschule Aachen Selektive Markierung der Glykane von Antikörpern mit modifizierten Nukleotidzuckern als Substrate von rekombinanten Galactosyltransferasen
EP1878747A1 (en) 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-engineered antibodies
US8093006B2 (en) 2009-04-02 2012-01-10 Hoffmann-La Roche Inc. Antibodies against human tweak and uses thereof

Also Published As

Publication number Publication date
EP2625200A1 (en) 2013-08-14
JP2013543383A (ja) 2013-12-05
MX343114B (es) 2016-10-25
EA201300418A1 (ru) 2013-09-30
TWI482630B (zh) 2015-05-01
TW201219054A (en) 2012-05-16
NZ607588A (en) 2014-02-28
CN103154029B (zh) 2015-11-25
CN103154029A (zh) 2013-06-12
JP5941049B2 (ja) 2016-06-29
MX2013003592A (es) 2013-05-31
KR101584416B1 (ko) 2016-01-13
AU2011311673B2 (en) 2015-09-17
US20120121583A1 (en) 2012-05-17
CA2809632A1 (en) 2012-04-12
BR112013007293A2 (pt) 2016-06-14
HK1186195A1 (zh) 2014-03-07
MA34642B1 (fr) 2013-11-02
SG188605A1 (en) 2013-04-30
CR20130108A (es) 2013-04-29
US9187564B2 (en) 2015-11-17
AR083336A1 (es) 2013-02-21
KR20130062369A (ko) 2013-06-12
ECSP13012542A (es) 2013-06-28
AU2011311673A1 (en) 2013-03-14
WO2012045671A1 (en) 2012-04-12
PE20131411A1 (es) 2013-12-16
PH12013500506A1 (en) 2017-08-23

Similar Documents

Publication Publication Date Title
CL2012002896A1 (es) Compuestos para tratamiento de enfermedades asociadas con proteinas amiloides o tipo amiloide; composicion farmacéutica que lo comprende; uso del compuesto para retener o incrementar la memoria cognitiva.
CL2014003110A1 (es) Anticuerpo anti-fcrn; secuencias que lo codifican; vector; célula huésped; proceso de producción; composición farmacéutica que lo comprende; uso para el tratamiento de enfermedad autoinmune; y ensayo para probar la capacidad de un anticuerpo para bloquear la actividad de fcrn humano.
BR112012009854A8 (pt) proteínas de ligação de antígeno il-23 humana
CL2014000114A1 (es) Anticuerpo que se une a r-espondina 1 humana (rspo1); polipéptido que comprende un anticuerpo; composición farmacéutica que comprende el anticuerpo; uso para inhibor el crecimiento de un tumor.
CL2016000438A1 (es) Anticuerpos humanizados que se unen específicamente al receptor del factor estimulante de colonias 1 (csf-1r); ácidos nucleicos; vectores de expresión, células huéspedes; procesos de producción; composiciones farmacéuticas; usos y métodos de tratamiento terapéutico para el tratamiento del cáncer y de la enfermedad fibrótica
CL2014000958A1 (es) Polipeptidos de anticuerpos que antagonizan cd4ol; acido nucleico que codifica dicho anticuerpo; vector y célula huesped que la comprenden; composicion farmacéutica; uso de dichos polipéptidos para tratar enfermedad inmunitaria.
CL2013002673A1 (es) Composicion que comprende un polipéptido aislado con actividad inhibidor de nav1.3 y nav1.7; composicion farmacéutica que comprende la composicion antes dicha; metodo para tratar dolor.
MX2018012166A (es) Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1).
CL2009001277A1 (es) Anticuerpo que enlaza especificamente el flt3 humano; fragmento de cualquiera de los anticuerpos antes dichos; acido polinucleico aislado; vector de expresion; celula recombinante; composicion farmaceutica y sus usos; producto que contiene el anticuerpo para tratar cancer
PE20181092A1 (es) Anticuerpos anti-pd1 y metodos de uso
AR101669A1 (es) Constructos de anticuerpos para cdh19 y cd3
CL2012000620A1 (es) Formulaciones farmaceuticas de un anticuerpo anti cd-20; uso de la formulacion para tratar enfermedad o trastorno que pueda corregirse mediante tratamiento con anticuerpo anti-cd20.
GT201300306A (es) Anticuerpos anti-angptl3 y usos de los mismos
MX2017001011A (es) Tratamiento de cancer de usando un receptor quimerico de antigeno anti-bcma.
CL2012002737A1 (es) Anticuerpo anti-cd40 humanizado; polinucleótido que lo codifica; composición farmacéutica que comprende dicho anticuerpo; y su uso para bloquear una respuesta inmunitaria mediada por cd40 humana.
CL2011002482A1 (es) Anticuerpo biespecificos que se une especificamente a las proteinas erbb-3 humana y c-met humana; acido nucleico que lo codifica; composicion farmaceutica que lo comprende; y su uso para tratar cancer
BR112016022814A8 (pt) composição farmacêutica e seu método de preparação, ácido nucleico, e dispositivo médico ou kit médico
CL2012001547A1 (es) Anticuerpo ligante de csf-1r humano; composicion farmaceutica que lo comprende; acido nucleico que lo codifica; vector de expresion recombinante; celula procariotica o eucariotica transformada; metodo de produccion; y su uso para tratar cancer.
CR20130134A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
CL2013000545A1 (es) Anticuerpo anti-ox40; acido nucleico que lo codifica; celula huesped; metodo de produccion; y su uso para tratar cancer o una enfermedad autoinmune.
DOP2015000110A (es) Anticuerpos anti-ceacam5 y usos de estos
CL2015002635A1 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
BR112013032717A2 (pt) coagonistas do receptor de glucagon/glp-1
CL2012000524A1 (es) Anticuerpo humanizado que se une a cdcp1 humana útil en el tratamiento del cáncer; composición farmacéutica; ácido nucleico, vector de expresión y célula huésped que lo comprende; y método para producir el anticuerpo.
BR112016030424A2 (pt) construções de anticorpo multiespecíficas